2019-2020 Influenza Season Update and Recommendations for Clinicians

Image of Continuing Education Credits abbreviation. = Free Continuing Education

Date: Tuesday, January 28, 2020

Time: 2:00pm-3:00pm (Eastern Time)

Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-012820 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – “2019–2020 Influenza Season Update and Recommendations for Clinicians” January 28, 2020 (Webcast), please visit TCEO and follow these 9 Simple Steps by March 2, 2020.

In order to receive continuing education (CE) for WD2922-012820 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars “2019–2020 Influenza Season Update and Recommendations for Clinicians” Tuesday, January 28, 2020 (Web on Demand), please visit TCEO and follow these 9 Simple Steps by March 3, 2022.

Overview

Influenza activity in the United States is elevated and is expected to continue at elevated levels for several more weeks. Nationally, influenza B/Victoria viruses have been most common followed by influenza A(H1N1)pdm09 viruses. The predominant virus varies by region and age group. There has been low circulation of influenza A(H3N2) and influenza B/Yamagata viruses. Annual vaccination is the best way to prevent influenza. CDC continues to recommend everyone six months of age and older get vaccinated for influenza. CDC also recommends antiviral medications to treat influenza. Antiviral treatment has shown clinical and public health benefit in reducing illness and lessening severe outcomes of influenza based on evidence from randomized controlled trials, meta-analyses of randomized controlled trials, and observational studies during past influenza seasons and during the 2009 H1N1 pandemic.

During this COCA Call, clinicians will learn about current 2019–2020 influenza activity and CDC’s recommendations for healthcare providers, including influenza vaccination and the appropriate use of antiviral medications.

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Describe the current status of influenza activity in the United States.
  2. Describe the circulating influenza viruses detected this season and explain the implications for clinicians.
  3. Describe antiviral testing and treatment recommendations for patients with suspected and confirmed influenza.

Angela J. P. Campbell, MD, MPH
Medical Officer
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Alicia P. Budd, MPH
Epidemiologist
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

A few minutes before the webinar begins on Tuesday, January 28, 2020, please click the link below to join the webinar:
https://zoom.us/j/209471168external icon

Or iPhone one-tap :
US: +16468769923,,209471168#  or +16699006833,,209471168#

Or Telephone:
Dial (for higher quality, dial a number based on your current location):

US: +1 646 876 9923  or +1 669 900 6833

Webinar ID: 209 471 168

International numbers available: https://zoom.us/u/anixAVglVexternal icon

WC2922 – 012820 (must be completed by 03/02/2020)
WD2922 – 012820 (must be completed by 03/03/2022)

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians
  • Contact Information:coca@cdc.gov
  • Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
  • Method of Participation:You may participate in the educational activity by viewing the program information above.
  • Fees: Continuing Education (CE) is free.

Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 1.0 contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

Image of acpe logo.CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-20-033-L04-P  and enduring 0387-0000-20-033-H04-P course category.

This activity has been designated as Knowledge-Based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

DISCLOSURE:

In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Planners have reviewed content to ensure there is no bias.

The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use, except Dr. Angela Campbell would like to disclose that she will discuss the off label use of antiviral medications for treatment of influenza.

CDC did not accept commercial support for this continuing education activity.

Page last reviewed: January 14, 2020